XRTX
XORTX Therapeutics Inc.
There isn't enough reported data to score XRTX yet.
XRTX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
XRTX's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
XRTX PE Valuation
XRTX has no meaningful PE right now: it lost money over the past year.
XRTX Forward outlook
There aren't enough analyst estimates for XRTX to show an outlook.
XRTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$2.74 | -$0.85 |
| Q1 2026 | -$2.64 | -$1.76 |
| Q4 2025 | -$2.99 | -$1.80 |
| Q3 2025 | -$2.34 | -142% |
| Q2 2025 | -$1.89 | -$1.62 |
| Q1 2025 | -$0.88 | +$7.19 |
| Q4 2024 | -$1.19 | +$14.19 |
XRTX is still losing money, but far less than before: $2.74 per share over the past year, against $15.38 at its worst in late 2023.
XRTX Quarterly Revenue
XRTX's revenue is shrinking: $0 last quarter.
XRTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $0 | +$815.3K |
| Q1 2026 | -$505.2K | +$142K |
| Q4 2025 | -$726.4K | +$164.1K |
| Q3 2025 | -$635.1K | +$139.9K |
| Q2 2025 | -$815.3K | -$69.7K |
| Q1 2025 | -$647.1K | +$659.4K |
| Q4 2024 | -$890.4K | +$417.4K |
| Q3 2024 | -$775K | +$303K |
XRTX has burned cash in almost every quarter: −$2M over the past year, against −$3M the year before.
XRTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +16% | +225K shares |
| 1 year | +114% | +860K shares |
| 3 years | +628% | +1.4M shares |
XRTX has 2M diluted shares, up 114% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
XRTX hasn't bought back shares in the past year.
XRTX Net Leverage
XRTX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
XRTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.8 | Oversold |
| Stochastic | 6.2 | Oversold |
XRTX's weekly RSI is 28 (oversold) and its Stochastic is 6 (oversold).
XRTX PE vs Healthcare Sector
| Metric | XRTX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
XRTX has no meaningful PE right now: it lost money over the past year.
XRTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.23 | 25% below |
| 20 week MA | $1.77 | 48% below |
| 50 week MA | $2.18 | 58% below |
| 100 week MA | $3.33 | 72% below |
| 200 week MA | $10.7 | 91% below |
XRTX is in a downtrend: it's below all five of its weekly moving averages, and 91% below its 200-week average.
XRTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $72.5 | $42.3 | -42% |
| 2021 | $42.3 | $90.0 | +113% |
| 2022 | $90.0 | $33.3 | -63% |
| 2023 | $33.3 | $11.6 | -65% |
| 2024 | $11.6 | $5.95 | -48% |
| 2025 | $5.95 | $2.77 | -53% |
| 2026 YTD | $2.77 | $0.92 | -67% |
XRTX has finished four years in a row lower, and it's down 67% so far in 2026.